HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Muyuan Foods - The Hog King in China Has Greater Potential and Resilience

Sichuan Kelun-Biotech Biopharm (6990.HK) Placement - Thoughts The Pipeline and Valuation Outlook

Pre-IPO Medtide (PHIP Updates) - Some Points Worth the Attention

Pre-IPO Zephyrm Bioscience - Despite Promising Pipeline, Investment Risk Is High

Pre-IPO Wuhan Dazhong Dental Medical - Valuation Performance May Disappoint Investors

Pre-IPO Jiangsu Hengrui Medicine - High Valuation Cannot Be Justified

Equity Capital Markets

Vigonvita Life Sciences / Equity Capital Markets

<ul>
<li>Due to fierce competition/VBP, generic drug business has little value, whose valuation should be zero. So, the future valuation performance of Vigonvita would be mainly based on innovative drug pipeline.</li>
<li>Since future demand of COVID-19 drug would decrease sharply, it’s recommended to calculate Vigonvita’s valuation by excluding COVID-19 projects. Vigonvita has to rely on other indication/candidates to support valuation outlook.</li>
<li>Post-Money valuation after Series C financing reached RMB4.45 billion.Short-term valuation is about RMB3-6 billion. If LV232 can be successfully developed, there will be greater room for growth in future valuation.</li>
</ul>


Due to fierce competition/VBP, generic drug business has little value, whose valuation should be zero. So, the future valuation performance of Vigonvita would be mainly based on innovative drug pipeline.
Since future demand of COVID-19 drug would decrease sharply, it’s recommended to calculate Vigonvita’s valuation by excluding COVID-19 projects. Vigonvita has to rely on other indication/candidates to support valuation outlook.
Post-Money valuation after Series C financing reached RMB4.45 billion.Short-term valuation is about RMB3-6 billion. If LV232 can be successfully developed, there will be greater room for growth in future valuation.


Pre-IPO Vigonvita Life Sciences - The Challenges Behind the Pipeline and the Outlook